Drugs / Fluzone
Fluzone
Trials 54
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT03945825 | Jun 2019 → Sep 2020 | influenza | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT02267733 | Oct 2014 → Dec 2015 | influenza, monoclonal gammopathy | Yale University | Completed | No outcome recorded |
| Phase 1 | NCT03453801 | Sep 2014 → Jan 2019 | influenza | Stanford University | Completed | No outcome recorded |
| Phase 1 | NCT01302990 | Feb → Jul 2011 | influenza | Medicago | Completed | No outcome recorded |
| Phase 1 | NCT00231907 | Sep 2005 → Mar 2007 | influenza | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT00231920 | Oct 2004 → Aug 2006 | influenza | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00336453 | Oct 2006 → Jul 2007 | influenza | Protein Sciences Corporation | Completed | No outcome recorded |
| Phase 28 trials · 1 missed | ||||||
| Phase 2 | NCT05291676 | Nov 2023 → Apr 2027 expected | influenza | Yale University | Recruiting | No outcome recorded |
| Phase 2 | NCT01181323 | Sep 2011 → May 2013 | influenza | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | Missed primary |
| Phase 2 | NCT01173211 | Sep 2010 → Nov 2011 | influenza | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT01011049 | Sep 2009 → May 2010 | influenza | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 2 | NCT00936468 | Sep 2009 → Jun 2010 | influenza | Colby Pharmaceutical Company | Completed | No outcome recorded |
| Phase 2 | NCT00905125 | Jun 2009 → Mar 2010 | influenza | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT00623181 | Jan → May 2008 | influenza | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 2 | NCT00283283 | Nov 2004 | influenza | U.S. Army Medical Research and Development Command | Completed | Mixed |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT00242424 | Sep 2005 → Sep 2006 | — | Seattle Children's Hospital | Completed | No outcome recorded |
| Phase 33 trials · 1 met primary | ||||||
| Phase 3 | NCT00395174 | Oct 2006 → May 2007 | influenza | Protein Sciences Corporation | Completed | No outcome recorded |
| Phase 3 | NCT00197288 | Oct 2005 → May 2006 | influenza | GlaxoSmithKline | Completed | Met primary |
| Phase 3 | NCT00232947 | Oct 2005 → Feb 2006 | influenza | ID Biomedical Corporation, Quebec | Completed | No outcome recorded |
| Phase 431 trials | ||||||
| Phase 4 | NCT06518577 | Sep → Dec 2024 | influenza | Duke University | Completed | No outcome recorded |
| Phase 4 | NCT06567860 | May 2024 → Feb 2025 | influenza | La Jolla Institute for Immunology | Completed | No outcome recorded |
| Phase 4 | NCT05170399 | Sep 2022 → Aug 2026 overdue | lymphoma | National Heart, Lung, and Blood Institute (NHLBI) | Recruiting | No outcome recorded |
| Phase 4 | NCT03023709 | Sep → Dec 2015 | influenza | Stanford University | Terminated | No outcome recorded |
| Phase 4 | NCT03028987 | Nov 2014 → Nov 2015 | influenza | Stanford University | Terminated | No outcome recorded |
| Phase 4 | NCT03028974 | Sep 2014 → Nov 2017 | influenza | Stanford University | Completed | No outcome recorded |
| Phase 4 | NCT03020537 | Oct → Dec 2013 | influenza | Stanford University | Completed | No outcome recorded |
| Phase 4 | NCT03023553 | Dec 2012 → Feb 2013 | influenza | Stanford University | Completed | No outcome recorded |
| Phase 4 | NCT02134184 | Oct → Dec 2012 | cytomegalovirus infection, influenza | Stanford University | Completed | No outcome recorded |
| Phase 4 | NCT01691339 | Sep → Nov 2012 | influenza | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 4 | NCT01691326 | Sep → Dec 2012 | influenza | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 4 | NCT01644149 | Jan → Feb 2012 | — | PharmaJet, Inc. | Completed | No outcome recorded |
| Phase 4 | NCT01430819 | Sep 2011 → Feb 2012 | influenza | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 4 | NCT02141581 | Aug 2011 → Dec 2014 | influenza | Stanford University | Completed | No outcome recorded |
| Phase 4 | NCT01422200 | Aug → Dec 2011 | Duchenne muscular dystrophy, congenital muscular dystrophy, spinal muscular atrophy | Children's Hospital Medical Center, Cincinnati | Completed | No outcome recorded |
| Phase 4 | NCT01262846 | Nov 2010 → Apr 2011 | HIV infectious disease | University of Pennsylvania | Completed | Mixed |
| Phase 4 | NCT01831934 | Sep 2010 → Dec 2011 | MELAS syndrome | Stanford University | Completed | No outcome recorded |
| Phase 4 | NCT03022396 | Sep 2010 → Jan 2011 | influenza | Stanford University | Completed | No outcome recorded |
| Phase 4 | NCT03020498 | Sep 2010 → Dec 2011 | influenza | Stanford University | Completed | No outcome recorded |
| Phase 4 | NCT01987349 | Sep 2009 → Jan 2010 | influenza | Stanford University | Completed | No outcome recorded |
| Phase 4 | NCT02133781 | Jul → Dec 2009 | influenza | Stanford University | Completed | No outcome recorded |
| Phase 4 | NCT00755274 | Sep 2008 → Jan 2009 | influenza | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 4 | NCT00743275 | Aug → Nov 2008 | influenza | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 4 | NCT00389857 | Oct 2006 → Sep 2007 | influenza | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 4 | NCT00258817 | Oct 2005 → Mar 2006 | influenza | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 4 | NCT00258830 | Sep 2005 → Feb 2006 | influenza | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 4 | NCT00138385 | Aug 2005 → Jun 2007 | influenza | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 4 | NCT00133510 | Nov 2004 → Sep 2006 | influenza | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 4 | NCT00831987 | Aug 2004 → Feb 2006 | influenza | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 4 | NCT00836953 | Sep 2003 → Jan 2004 | influenza | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 4 | NCT00138281 | ? → Nov 2005 | influenza | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase not applicable4 trials | ||||||
| — | NCT02559505 | Oct 2015 → Jul 2020 | influenza | University of Rochester | Completed | Mixed |
| — | NCT01733056 | Jan 2011 → Jan 2013 | immunodeficiency disease | Emory University | Completed | No outcome recorded |
| — | NCT01044095 | Nov 2009 → Jul 2010 | influenza | Armed Forces Research Institute of Medical Sciences, Thailand | Completed | No outcome recorded |
| — | NCT00170508 | Jun → Aug 2005 | influenza | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Comparator or background therapy33 trials | ||||||
| Phase 0 | NCT01385215 Comparator | Apr → Jun 2011 | — | John Sundy | Completed | No outcome recorded |
| Phase 1 | NCT01354379 Comparator | May 2011 → Jun 2012 | — | NanoBio Corporation | Completed | No outcome recorded |
| Phase 1/2 | NCT02263040 Comparator | Oct 2014 → Jul 2016 | influenza | Mount Sinai Hospital, Canada | Completed | No outcome recorded |
| Phase 1/2 | NCT01224262 Background | Sep 2010 → Dec 2011 | influenza | Liquidia Technologies, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT01248208 Comparator | Sep 2010 → Sep 2011 | food allergy | Walter Reed Army Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT04176133 Background | Oct 2019 → Mar 2022 | — | Robert J. Pignolo | Completed | No outcome recorded |
| Phase 2 | NCT02918006 Comparator | Aug 2016 → Aug 2017 | influenza | Vaxart | Completed | No outcome recorded |
| Phase 2 | NCT01974895 Comparator | Oct 2013 → Feb 2014 | influenza | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT01685372 Comparator | Sep 2012 → Sep 2015 | HIV infectious disease, disease related to solid organ transplantation, rheumatic disorder | University of Colorado, Denver | Completed | No outcome recorded |
| Phase 2 | NCT00551031 Comparator | Oct 2007 → Jun 2008 | influenza | Sanofi | Completed | No outcome recorded |
| Phase 2 | NCT00253734 Comparator | Nov 2005 → Oct 2006 | influenza | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 3 | NCT02255279 Comparator | Oct 2014 → May 2015 | influenza | Novartis Vaccines | Completed | Met primary |
| Phase 3 | NCT01773928 Comparator | Jan → Apr 2013 | influenza | Alachua Government Services, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01218646 Comparator | Oct 2010 → Mar 2011 | influenza | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT00980005 Comparator | Oct 2009 → Mar 2010 | influenza | GlaxoSmithKline | Completed | Met primary |
| Phase 3 | NCT00976027 Comparator | Sep 2009 → May 2011 | influenza | Sanofi | Terminated | No outcome recorded |
| Phase 3 | NCT00959049 Comparator | Sep → Dec 2009 | influenza | Seqirus | Completed | Met primary |
| Phase 3 | NCT00764790 Comparator | Oct 2008 → Mar 2009 | influenza | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00539864 Comparator | Sep 2007 → Apr 2008 | influenza | Protein Sciences Corporation | Completed | No outcome recorded |
| Phase 3 | NCT00383123 Comparator | Nov 2006 → Oct 2007 | influenza | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01389479 Comparator | Jan → May 2005 | influenza | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 4 | NCT04101838 Comparator | Apr 2021 → May 2026 overdue | influenza | University of Alabama at Birmingham | Active not recruiting | No outcome recorded |
| Phase 4 | NCT03614975 Comparator | Sep → Dec 2018 | influenza | Richard Zimmerman MD | Completed | No outcome recorded |
| Phase 4 | NCT03722589 Comparator | Sep 2018 → Jul 2020 | influenza | Centers for Disease Control and Prevention | Completed | No outcome recorded |
| Phase 4 | NCT02871206 Comparator | Nov 2016 → Jun 2019 | influenza | McMaster University | Completed | No outcome recorded |
| Phase 4 | NCT03068949 Comparator | Oct 2015 → Jun 2020 | influenza | University of Rochester | Completed | No outcome recorded |
| Phase 4 | NCT02563184 Comparator | Sep → Dec 2015 | chronic obstructive pulmonary disease | Banner Health | Unknown | No outcome recorded |
| Phase 4 | NCT02297542 Comparator | Oct 2014 → Dec 2019 | — | Health Sciences North Research Institute | Unknown | No outcome recorded |
| Phase 4 | NCT00735475 Comparator | Oct 2008 → Jan 2009 | influenza | Seqirus | Completed | No outcome recorded |
| Phase 4 | NCT00538512 Comparator | Sep 2007 → May 2008 | influenza | University of Michigan | Completed | No outcome recorded |
| — | NCT01737710 Comparator | Oct 2012 → May 2013 | atopic eczema | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| — | NCT01189123 Comparator | Aug 2010 → Aug 2011 | — | Vanderbilt University | Completed | No outcome recorded |
| — | NCT00902278 Comparator | Oct 2008 → Apr 2016 | — | University of Massachusetts, Worcester | Completed | No outcome recorded |
Press releases naming this drug 1 release
Evidence & citations 15 cited values
Every value below carries the sentence it was read from. 87 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fluzone | “Study subjects will be randomized 1:1:1 to receive one of the following three 2010-2011 seasonal inactivated trivalent influenza vaccines: Fluarix®, Agriflu®, or Fluzone® (60...” NCT01173211 ↗89“The purpose of this study is to compare two licensed influenza vaccines (Fluzone and Fluarix) in terms of the immune response elicited and the safety/ any symptoms that may...” NCT00197288 ↗ “Licensed trivalent influenza vaccine (TIV): 2005-2006 formulation containing 15μg of each hemagglutinin derived from A/Wisconsin (H3N2), A/New Caledonia (H1N1) and...” NCT00395174 ↗ “2006-2007 formulation of Fluzone, (sanofi-pasteur, Swiftwater, PA)-7.5 μg of each hemagglutinin antigen: A/New Caledonia/20/99 (H1N1), A/Wisconsin/67/05 (H3N2), and...” NCT00336453 ↗ “MF59-adjuvanted influenza vaccine (FLUAD®) elicits higher immune responses than a non-adjuvanted influenza vaccine (Fluzone®): A randomized, multicenter, Phase III pediatric...” PMID 28925801 ↗ Jan 2018 “The purpose of this study is to generate additional data on the immunogenicity and safety of revaccination with Fluzone Intradermal (ID) or Fluzone Intramuscular (IM) vaccine.” NCT01011049 ↗ “A Non-Inferiority Comparison of Fluviral™ Influenza Vaccine to a U.S. Licensed Inactivated Split-Virion Vaccine (Fluzone®) in Adults ≥ 50 Years Old Living in the Community” NCT00232947 ↗ “2005-6 Fluzone, pediatric formulation of trivalent inactivated influenza vaccine (sanofi pasteur) administered to infants at 2 and 3 months of age” NCT00242424 ↗ “The aim of this study is to determine the efficacy of Fluzone High Dose vaccine and that of Fluzone® vaccine in the elderly.” NCT00976027 ↗ “0.5 mL of Fluzone (2011-2012 Northern Hemisphere formulation) influenza vaccine administered via subcutaneous route once” NCT01422200 ↗ “older adults (≥65 years, n=582) were randomized to receive SD-SVV or HD-SVV (Fluzone®) from 2014/15 to 2017/18” PMID 35128529 ↗ May 2021 |
| Known as | Fluzone (2012-2013 Formulation) | “Fluzone® (2012-2013 Formulation)” NCT01691339 ↗ |
| Known as | Fluzone (Influenza Virus Vaccine) 2012-2013 Formulation | “Fluzone® (Influenza Virus Vaccine) 2012-2013 Formulation” NCT01691326 ↗ |
| Known as | fluzone by sanofi pasteur | “Biological: fluzone by sanofi pasteur” NCT01189123 ↗ |
| Known as | Fluzone High-Dose | “Fluzone High-Dose 0.7 ml intramuscular injection, standard as recommended by manufacturer” NCT05291676 ↗ |
| Known as | Fluzone Quadrivalent | “one of two standard dose egg-based vaccines (Fluzone® Quadrivalent by Sanofi Pasteur, 15µg of HA per strain and Fluarix® Quadrivalent by GlaxoSmithKlein, 15µg of HA per strain)” NCT03722589 ↗1“Fluzone® Quadrivalent: Quadrivalent influenza virus vaccine” NCT03028974 ↗ |
| Known as | Fluzone vaccine | “Fluzone vaccine administered in both May-June and in September-October for each participant.” NCT06567860 ↗ |
| Known as | High dose fluzone (Sanofi-Pasteur) | “High dose fluzone (Sanofi-Pasteur)” NCT01189123 ↗ |
| Known as | IIV4 | “Participants will receive the current seasonal quadrivalent, inactivated influenza vaccine (IIV4)/Fluzone® given intramuscularly to confirm the safety of administering the...” NCT03023709 ↗ |
| Known as | Influenza Virus Vaccine | “Fluzone (Influenza Virus Vaccine) Suspension for Intramuscular Injection 2013-2014 Formula.” NCT03020537 ↗ |
| Known as | TIV | “trivalent inactivated influenza vaccine (TIV, Fluzone®, sanofi pasteur 2005-6 pediatric formulation)” NCT00242424 ↗1“0.5 ml of Inactivated Trivalent Influenza Vaccine (TIV), Fluzone® given intramuscularly (IM)” NCT01181323 ↗ |
| Known as | Trivalent Subviron Influenza vaccine | “Trivalent Subviron Influenza vaccine (Fluzone)” NCT00133510 ↗ |
| Known as | US Licensed Influenza Virus Vaccine | “US Licensed Influenza Virus Vaccine (Fluzone®)” NCT00735475 ↗ |
| Modality | Vaccine | “inactivated vaccine” NCT00138281 ↗ |
| Route | Intramuscular | “inactivated vaccine given IM” NCT00138281 ↗ |